Background: Shen-Qi-Wan (SQW), a commonly used prescription against chronic kidney disease (CKD) in Traditional Chinese Medicine (TCM), has a nephroprotective action in adenine-induced kidney injury. However, the mechanism of SQW in renal injury remains unclear.Objective: This study was undertaken to measure the effect of SQW on peritubular capillary injury both in vivo and in vitro assays.Methods: The effect of SQW on the peritubular capillary injury was evaluated according to measuring hypothalamic-pituitary-adrenal (HPA) function, inflammatory cytokines, VEGF (vascular endothelial growth factor), CD34 (Cluster of differentiation 34), and AQP1 (Aquaporin 1) levels in the kidney, cell migration, and lumen forming capacity.Results: SQW supplementation could ameliorate dysfunction of the HPA and renal function loss induced by adenine. SQW also significantly inhibited the inflammatory cytokines including MCP-1 (monocyte chemotactic protein-1) and VCAM-1 (vascular cell adhesion molecule-1) level. Alternatively, SQW administration showed an ameliorating effect from the toxicity and alleviated the injury of capillaries around renal tubules instigated by adenine through increasing AQP1 mRNA and protein level. SQW medicated the serum enhanced the migration and lumen formation ability of HMEC-1 cells, and significantly increased AQP1 protein level. Moreover, AQP1 knockdown efficiently inhibited the migration and lumen formation ability in HMEC-1 cells, and weakened the effect of SQW medicated serum. Conclusion: These results suggested that SQW attenuated peritubular capillary injury in adenine-induced CKD model rats through boosting angiogenesis in endothelial cell, and AQP1 may be a potential target of SQW for treating the renal injury.